Current Report Filing (8-k)
May 11 2023 - 7:04AM
Edgar (US Regulatory)
0001760542false00017605422023-05-112023-05-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2023
HOOKIPA PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | | 001-38869 | | 81-5395687 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
350 Fifth Avenue, 72nd Floor, Suite 7240 | | |
New York, New York | | 10118 |
(Address of principal executive offices) | | (zip code) |
Registrant’s telephone number, including area code: +43 1 890 63 60
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of exchange on which registered |
Common stock, $0.0001 | | HOOK | | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On May 11, 2023, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the First Quarter 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
In April, the Company presented preclinical data resulting from an exploratory, non-commercial research effort as an oral presentation at the American Association for Cancer Research Annual Meeting highlighting the potential of its arenaviral immunotherapy in combination with Roche’s targeted PD1-IL2 variant (PD1-IL2v) as a potential promising next-generation immunotherapy. The data show that PD1-IL2v treatment subsequent to arenaviral immunotherapy further strengthens T cell responses, resulting in strong anti-tumor activity and high tumor cure rates. Similar results were seen for both tumor-associated oncoviral antigens and self-antigens, underscoring the potential of the combination for multiple tumor types.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| HOOKIPA Pharma Inc. |
Date: May 11, 2023 | By: | /s/ Joern Aldag |
| | Joern Aldag |
| | Chief Executive Officer |
| | (Principal Executive Officer) |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024